Drug Trial Radar · NCT02030821
TXA vs. Amicar in Total Knee and Hip Arthroplasty
Last checked: Nov 20, 2026Latest source record: Dec 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
246
Actual
Start
Jan 2015
Primary completion
Nov 12, 2017
Study completion Nov 12, 2017
Sponsor
- Lead sponsor
- Duke UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the relative effectiveness of two drug agents, Tranexamic acid (TXA) and aminocaproic acid (Amicar), that act through a similar mechanism of action. These agents are used to decrease blood loss that is a result of major surgery, like total joint arthroplasty. A secondary goal will be investigate the cost-analysis of total hospitalization. Both TXA and Amicar are both currently used in the care of patients undergoing total joint arthroplasty. Subjects will be randomly assigned to the TXA or Amicar arm. All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization stay. Our Hypothesis is that TXA and Amicar will have similar effectiveness in preventing intraoperative blood loss and the need for transfusion post-op than Amicar. A detailed cost analysis will show that the overall cost of performing the operative procedure, including transfusions, OR time, and total costs associated with admission cost will be more decreased with Amicar as compared to TXA.
Conditions
- Blood Loss
- Hip Arthritis
- Knee Arthritis
Interventions
AmicarDrug
Subjects randomized to receive Amicar will receive this during surgical intervention
TXADrug
Subjects randomized to receive TXA will receive this during surgical intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge)Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
- Number of TransfusionsTime frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
- Difference in Preoperative and Lowest Postoperative HemoglobinTime frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Duke University Medical Center
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.